Advertisement
Research Article

Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2

  • Morris E Feldman,

    Affiliation: Howard Hughes Medical Institute and Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, United States of America

    X
  • Beth Apsel,

    Affiliation: Howard Hughes Medical Institute and Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, United States of America

    X
  • Aino Uotila,

    Affiliation: Department of Molecular Biology, University of Geneva, Switzerland

    X
  • Robbie Loewith,

    Affiliation: Department of Molecular Biology, University of Geneva, Switzerland

    X
  • Zachary A Knight,

    Affiliation: Howard Hughes Medical Institute and Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, United States of America

    ยค Current address: The Rockefeller University, New York, New York, United States of America

    X
  • Davide Ruggero,

    Affiliation: School of Medicine and Department of Urology, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, United States of America

    X
  • Kevan M Shokat mail

    To whom correspondence should be addressed. E-mail: shokat@cmp.ucsf.edu

    Affiliation: Howard Hughes Medical Institute and Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, United States of America

    X
  • Published: February 10, 2009
  • DOI: 10.1371/journal.pbio.1000038

Viewed info

Cited info

Saved info

Discussed info

Questions or concerns about usage data? Please let us know.